Page 2 - Rob Schott News Today

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years

No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood

Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec

SGMO earnings call for the period ending October 3, 2021.

Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated - All four patients in the first two dose cohorts exhibited above normal a-Gal A activity, which was maintained

Operator Good day, and thank you for standing by. Welcome to the Sangamo First Quarter 2021 Teleconference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Aron Feingold, Head of Corporate Communications. Please go ahead. Aron Feingold -- Head of Corporate Communications Good afternoon, and thank you for joining us today. With me this afternoon on this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Ch...

And what about the picnickers? Will they lug their picnic baskets and paraphernalia down and back again? Go ahead and install picnic tables and benches for those fair-weather days when they can be used, let some food trucks set up and see if the location proves to be viable, but leave the road and parking spaces as they are. City hall’s plan for Clover Point is just the latest proof of the fact that we are paying too many people too much money to daydream impractical notions and doodle fan...

Bookmark of this page has been deleted. Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo�...